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1 Introduction 
 
1.1 Lithium 
1.1.1 A historical and clinical approach  
 
Lithium is a soft, silver white metal, which belongs to the group of alkali metals 
together with sodium and potassium. Normally, all tissues and body fluids 
contain lithium in trace amounts (<0.2 mEq/L) (1). Dietary sources of lithium salt 
include: vegetables, plant-derived foods and drinking water. It is also found in 
almost all igneous rocks. Lithium salt has a long history of human consumption 
beginning in the 1800s (2). Furthermore, lithium has been used in treatment of 
many diseases including epilepsy, diabetes, gout and insomnia. In 1949, lithium 
was introduced for the first time into the modern psychiatrics. In 1974, it has 
been approved by the US Food and Drugs as a treatment for bipolar disorder. 
Until now, lithium treatment has remained the "gold standard" therapy for 
patients with mood disorders. Lithium has also been used as an effective 
augmenting therapy for other antidepressant drugs, especially the refractory 
depression when the patients respond ineffectively to adequate usual dose (3, 
4) . Lithium is the only drug that consistently reduces the suicidal rate in patients 
with neuropsychiatric disorders (5, 6). Moreover, lithium has been utilized as 
prophylaxis for cluster headaches (7, 8).  
In the last years, lithium has been demonstrated to be an effective 
neuroprotective agent in acute brain injuries and chronic neurodegenerative 
disorders (9, 10), since it is the only agent that stimulates the anti-apoptotic 
pathways in the brain. These observations made lithium more interesting to the 
medical field. However, one of the major limitations of lithium is its narrow 
therapeutic index (2, 11). Recent studies have demonstrated that lithium could 
promote longevity in humans (12, 13). In spite of its extensive clinical 
applications, the underlying mechanism of its therapeutic action remains to be 
incompletely investigated (14).  
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1.1.2 Pharmacokinetics 
 
Lithium is rapidly and completely absorbed from the gastrointestinal tract (GIT), 
reaching the peak plasma concentration within 1 to 2 hours following oral 
intake. Its half-life is about 12 to 27 hours. It can be increased up to 58 hours in 
elderly and chronic kidney disease (CKD) patients. Lithium is excreted without 
metabolism by the kidney; around 95% of absorbed lithium is excreted in the 
urine and less than 1% in the faeces. Lithium is filtered freely by the glomerulus; 
80% of the filtered lithium is reabsorbed in the proximal tubule, whereas 20% is 
reabsorbed in the thick ascending limb, connecting tubule and cortical collecting 
duct (1). 
1.1.3 Dose and route of administration 
 
In humans, lithium dose must be adjusted individually according to serum 
lithium concentration, and clinical response of the patient. The initial 
recommended dose is usually 450 - 900 mg per day, divided into 2 to 3 doses, 
targeting lithium serum concentration between 0.6 – 1.2 mmol/L. Lithium is 
generally administered orally as lithium carbonate (capsule) or lithium citrate 
(Syrup) (1). In animals, lithium can be administered through drinking water, food 
or directly by subcutaneous or intraperitoneal injection. Studies on rats have 
demonstrated that lithium carbonate in drinking water and intraperitoneal 
injection of lithium chloride have similar effects (15). 
1.1.4 Side effects 
 
Lithium has a narrow therapeutic index 0.6 – 1.0 mmol/L, therefore the lithium 
serum concentrations have to be closely monitored in order to prevent toxic side 
effects, which are observed when serum lithium concentrations are above 1.5 
mmol/L. Short term side effects of lithium include headache, nausea, vomiting, 
diarrhoea and muscle weakness. Long term side effects on the other hand 
include nephrogenic diabetes insipidus (NDI), hand tremor, weight gain, 
hypothyrodism, hyperthyroidism, hyperparathyroidism and hypercalcemia (16-
19).  
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Fig. 1. Neuroprotective effects of lithium. 
Lines with solid arrows represent stimulatory connections; lines with flattened ends 
represent inhibitory connections. Dashed lines represent pathways with reduced 
activity as a result of lithium treatment.  
 
1.1.5 The mechanisms of action 
 
Lithium exerts its neuroprotective effects through multiple intersecting 
pathways, but the precise mechanisms of its action are still under investigation. 
Many studies have demonstrated that lithium prolongs cell survival through 
activating brain-derived neurotrophic factor (BDNF) and thereby stimulating 
anti-apoptotic pathways. In addition, lithium inhibits a large number of pro-
apoptotic factors through inhibiting glycogen synthase kinase-3 (GSK-3) and N-
methyl-D-aspartate (NMDA)-receptor-mediated calcium influx. All these 
changes together shift the Bcl-2 family member ratio towards the anti-apoptotic 
members, preventing the cytochrome c release, and inhibiting the caspase 
activation. Therefore, lithium prolongs cell survival through the stimulation of the 
anti-apoptotic and the inhibition of the pro-apoptotic pathways. It also up-
regulates anti-inflammatory cytokines and down-regulates the pro-inflammatory 
cytokines through suppression of NF - κB (Fig. 1) (20, 21). 
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1.2 Lithium and GSK-3 
 
The discovery that lithium inhibits GSK-3 raised the possibility that impaired 
inhibition of GSK-3 is associated with mood disorders. GSK-3 activity is found to 
be elevated in postmortem brains of depressed suicide victims. This 
observation suggests that GSK-3 inhibition may contribute to anti-suicidal 
effects of lithium. Moreover, varieties of pharmacological and molecular studies 
have demonstrated that inhibition of GSK-3 reduces both depression and 
manic-like behaviors (22, 23). 
1.2.1 GSK-3 
 
GSK-3 is a multifunctional serine/threonine protein kinase, which is ubiquitously 
expressed in the body with particularly high levels in the brain. GSK-3 has two 
isoforms α and β, both of which are ∼98% identical in their catalytic cores, but 
differ in the N- and C-terminals. Both isoforms are encoded by different genes 
(GSK-3α,-51KDa and GSK-3β,-47KDa). Several studies report that both 
isoforms play similar roles in several signalling pathways and that lithium 
effectively inhibits both isoforms (24). GSK-3 is one of the few kinases that are 
constitutively active in cells under resting conditions. GSK-3 activity can be 
inhibited by a variety of extracellular stimuli including insulin, epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) and Wnt ligands. GSK-3 is 
inhibited upon phosphorylation at serine 21 in GSK-3α and serine 9 in GSK-3β 
and it is regulated by PI3K/Akt, PKC and PKA kinases (23). Several studies 
suggest that GSK-3 plays a central role in many important signaling pathways 
and that aberrant GSK-3 signaling is associated with many pathologies 
including heart failure, bipolar disorder, diabetes mellitus, Alzheimer’s disease, 
aging, inflammation and cancer. Therefore, GSK-3 is regarded as a prominent 
therapeutic target and GSK-3 inhibitors, such as lithium could potentially be 
used for the treatment of these disorders (25, 26). 
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Fig.  2. Interactions between lithium and GSK-3.  
GSK-3 catalyzes the phosphorylation of many protein substrates in the presence 
of Mg2+–ATP. Lithium is a competitive inhibitor of the Mg2+, which results in 
inhibition of the activity of GSK-3. Blue arrows indicate the activation of GSK-3 
signaling. Red arrows indicate the inhibition of GSK-3 activity. 
1.2.2 The effects of lithium on GSK-3 
 
Lithium inhibits GSK-3 through direct and indirect mechanisms. Under normal 
physiological conditions GSK-3 catalyzes the reaction of multiple protein 
substrates in the presence of Mg2+-ATP. Lithium inhibits the GSK-3 directly 
through a competitive inhibition of Mg2+ leading to disrupted catalytic functioning 
of GSK-3 (27, 28). However, the indirect mechanism is through the inhibition of 
GSK-3 phosphorylation. The exact mechanism by which lithium phosphorylates 
GSK-3 is not exactly known. It could be through the inhibition of phosphatase, 
which is a  protein responsible for GSK-3 reactivity (Fig. 2) (29).  
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1.3 Lithium and nephrogenic diabetes insipidus 
 
Lithium salts significantly affects the renal function as it interferes with 
antidiuretic hormone (ADH), thus resulting in nephrogenic diabetes insipidus 
(NDI). NDI is a clinical syndrome characterised by reducing the urinary 
concentrating ability due to the resistance of the kidney against the action of 
arginine-vasopressin (AVP). NDI occurs in 40% of lithium treated patients (18). 
NDI has been detected as early as 8 weeks in humans (30) and within 5 - 7 
days in rodents following lithium treatment (31). The mechanisms through which 
lithium induces NDI remain incompletely understood. Recent studies 
demonstrate that GSK-3 could play an important role in the mechanism of 
lithium induced NDI. This speculation is based on the observation that the time 
course of GSK-3 inhibition coincides with the decrease of AQP2 expression and 
polyuria in lithium treated mice (32). 
1.3.1 Lithium transporters protein 
 
Lithium is not like the other anti-depressant drugs; it is not bound to the cellular 
receptor, rather, it enters the cells predominantly via different sodium or 
potassium transporters, channels or exchangers (1). Two key entry points for 
lithium are through ENaC and Na/H exchanger.  
ENaC is the major channel for sodium reabsorption in collecting duct. Sodium 
crosses the apical membrane through ENaC and is actively exported from the 
cell in basolateral membrane through sodium/potassium adenosine 
triphosphatase (Na+/K+-ATPase). In the collecting duct, lithium can cross the 
apical membrane through ENaC transporters, which is more permeable to 
lithium than sodium.  Unlike sodium, lithium is not exported from the cells by 
Na+/K+-ATPase. ENaC is upregulated by aldosterone and is inhibited by low 
concentrations of amiloride (33-35).  
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Na/H exchanger is responsible for sodium reabsorption across the proximal 
tubule. Na/H exchanger is also an amiloride sensitive channel. Blocking of both 
ENaC and Na/H exchanger by amiloride results in the reduction of lithium 
transport within the cell, and ultimately prevents the development of lithium 
induced NDI (36). Another lithium transporter is the sodium potassium chloride 
cotransporter 2 (NKCC2), it is found in the apical membrane of the thick 
ascending limb of the loop of Henle and it is inhibited by furosemide (1). 
1.3.2 Pathophysiology of lithium induced NDI 
 
Under normal physiological conditions, specialized membrane channel proteins 
called aquaporin 2 (AQP2) facilitate water transport across the apical 
membrane. The AQP2 channel, which is regulated by AVP, is a major 
physiological regulator of renal water excretion. In response to anti-diuretic 
stimuli, the pituitary gland secretes AVP, which binds to the V2 vasopressin 
receptor (V2R) in the basolateral membrane of the principle cell in the collecting 
duct. This results in the activation of adenylate cyclase through G protein and 
increases intracellular cAMP, and ultimately, cAMP activates the protein kinase 
A (PKA), which in turn stimulates the AQP2 transcription and insertion into the 
apical membrane of the collecting duct allowing water reabsorption and an 
increase of urine concentration (Fig. 3 a) (30, 37-39). 
Several studies have demonstrated that lithium reduces AQP2 protein 
abundance in the renal collecting duct via the inactivation of adenylyl cyclase 
and subsequent inhibition of PKA. The down-regulation of AQP2 channel leads 
to reduced water reabsorption and an increased urinary excretion. It continues 
to be debated whether lithium induces NDI through a direct effect or as result of 
GSK-3 inhibition (40-42). GSK-3 inactivation modulating adenylate cyclase 
activity and cAMP generation (43). Furthermore, Rao et al., 2005 demonstrated 
that the inhibition of GSK-3 by LiCl up-regulates renal medullary interstitial 
cyclooxygenase 2 (COX2) and prostaglandin E2 (PGE2), which are known to 
antagonize AVP (Fig. 3 b) (44). 
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Fig. 3. Sodium and water reabsorption. 
A. Under physiological conditions sodium crosses the apical membrane through ENaC 
and is actively exported from the cell by the Na+,K+-ATPase. 
B. Lithium crosses the apical membrane through ENaC and prevents sodium entry. It is 
not exported from the cell by the Na+,K+-ATPase and accumulates intracellularly leading 
to inhibition of GSK-3. 
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1.4 Fibroblast growth factors (FGFs) 
 
FGFs are polypeptide, multifunctional growth regulators, affecting a wide variety 
of physiological events. The FGF family is comprised of 22 members that have 
a wide variety of functions contributing to organogenesis, tissue remodelling, 
nervous system control, angiogenesis and regulation of metabolism. FGFs are 
best known for their regulatory roles in cell growth, differentiation, and 
morphogenesis in early stages of neural development and have recently been 
discussed as switch genes, biomarkers, and treatment targets for affective 
disorders (45, 46). A correlation between antidepressant treatments and FGF 
expression in the cerebral cortex and hippocampus has been observed (47, 48). 
Moreover, patients suffering from major depressive disorders have deregulated 
transcript levels of several FGFs (49). A dysregulation of the FGF system in 
major depressive disorders involves two specific FGF receptors, FGFR2 and 
FGFR3 (50, 51).  
FGFs exhibit diverse modes of action, mechanisms of secretion and ultimate 
biological consequences. Therefore, FGF families are grouped into three 
groups according to their mechanisms of action: intracrine, paracrine and 
endocrine FGFs (51).  
• Paracrine FGFs mediate their biological responses in FGFR-dependent 
manner and carry out an important function in developmental processes. 
The members of paracrine FGFs subfamilies include FGF1/2/5, 
FGF3/4/6, FGF7/10/22, FGF8/17/18 and FGF9/16/20. 
•  Intracrine FGFs are intracellular molecules that regulate the function of 
voltage gated sodium channels in FGFR-independent manner. 
• Endocrine FGFs include FGF15/19, FGF21 and FGF23. they emerge as 
regulators of metabolism and are thought to mediate their biological 
responses in FGFR-dependent manner (52). 
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1.4.1 Fibroblast growth factor 23 (FGF23) 
  
FGF23 is a phosphaturic peptide hormone with an N-terminal and C-terminal 
region, belonging to the FGF19 subfamily of endocrine FGFs. FGF23 has been 
identified as a gene mutation in patients afflicted with autosomal dominant 
hypophosphatemic rickets (ADHR) (53). FGF23 has been found to be highly 
identical in both humans and mice. In humans, the FGF23 gene is located in 
chromosome 12, while in mice, it is located in chromosome 6 (54, 55). FGF23 is 
a powerful inhibitor of ageing, lack of FGF23 can lead to premature appearance 
of a wide variety of age related disorders such as osteopenia, osteoporosis, 
impaired angiogenesis, enhanced erythrocyte turnover, pulmonary emphysema, 
skin atrophy, infertility, hearing loss, neuron degeneration, Parkinson’s disease, 
cognitive impairment, neoplasm and inflammation (56, 57). FGF23 is 
predominantly expressed in osteocytes and the osteoblasts in the bone. It is 
also expressed in the parathyroid gland, small intestine, salivary gland, and to a 
lower extent, in the thymus, skeletal muscle, brain, liver, mammary gland and 
heart (58, 59). 
1.4.1.1 FGF23 function 
 
FGF23 is an important regulator of phosphorus and 1,25-
dihydroxycholecalciferol (1,25(OH)2D3) metabolism. It is also required for the 
maintenance of normal bones and mineral homeostasis. Transgenic mice with 
FGF23 over-expression develop hypophosphatemia, phosphaturia and low 
serum 1,25(OH)2D3 levels (60, 61). Knockout mice with FGF23 ablation and 
humans with homozygous missing mutations in FGF23 exhibit 
hyperphosphatemia, an increased 1,25(OH)2D3 serum level, a shortened life 
span and vascular calcifications (62, 63). The main known physiological function 
of FGF23 is to regulate serum phosphate and 1,25(OH)2D3 level. In order to do 
these functions, FGF23 requires a cofactor known as α-klotho to mediate its 
effects through FGFRs (57).  
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1.4.1.2 FGFR - α klotho complex 
1.4.1.2.1 Klotho 
 
Klotho was identified as an aging-suppressor gene, which extends life span 
when over-expressed and accelerates the development of aging-like 
phenotypes when knockout in mice (64-66). The klotho family includes two 
isoforms, α-klotho and β-klotho. α-klotho is a single-pass transmembrane 
protein functioning as an obligate co-receptor for FGF23 and is mainly 
expressed in the kidney and the epithelium of the choroid plexus in the brain 
and to a lower extent in the pituitary gland, placenta, skeletal muscle, urinary 
bladder, aorta, pancreas, testis, ovary and colon (67).  
The klotho knockout mice exhibit many ageing-like phenotypes after 3 - 4 
weeks including growth retardation, extensive soft tissue calcification, a 
decrease in life span paralleled by osteopenia/osteoporosis, endothelial 
dysfunction, impaired angiogenesis, sinoatrial node dysfunction with sudden 
cardiac arrest, enhanced erythrocyte turnover, pulmonary emphysema, skin 
atrophy, hypogonadotropic  hypogonadism, infertility, muscle atrophy, hearing 
loss, neuron degeneration, Parkinson’s disease, cognition impairment, 
neoplasm, inflammation and tissue fibrosis (66-78). 
Identification of klotho as an obligate co-receptor for FGF23 was based on the 
observations that both klotho and FGF23 knockout mice exhibit very similar 
phenotypes. The importance of α-klotho in FGF23 signaling is illustrated by 
several studies on humans and animals, where the loss of α-klotho results in 
the end-organ resistance to FGF23. Recent studies have identified α-klotho as 
being a necessary cofactor for FGF23, since it increases the affinity of FGF23 
to their receptors by changing the FGFR into a specific FGF23 receptor. 
Therefore, FGF23 target organs are defined by the co-expression of α-klotho 
and FGFRs. 
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1.4.1.2.2 FGF receptors 
 
Four types of FGFR have been identified in humans and mice. Only FGFR1, 
FGFR3, and FGFR4  are expressed in the renal proximal tubule (79). FGF23 
binds to FGFR, but with low affinity, while it binds to FGFR/α-klotho complex 
with much higher affinity. Several studies have demonstrated that FGF23 
signals via renal FGFR1 and 3 regulate phosphate reabsorption (80), but other 
studies have suggested that only FGFR1 is the predominant receptor for the 
FGF23 phosphaturic effect. At the same time, FGF23 has been found to 
regulate the renal synthesis of vitamin D3 via renal FGFR3 and 4 (81, 82). 
1.4.1.3  FGF23 target organs 
1.4.1.3.1 Renal 
 
The kidney is a principal target organ for FGF23. The primary physiological 
function of FGF23 is to inhibit the renal phosphate reabsorption via NaPT and 
suppress the renal synthesis of 1,25(OH)2D3. FGF23 regulates 1,25(OH)2D3 
synthesis through inhibition of Cyp27b1 to decrease its production and 
stimulation of Cyp24A1 in a bid to increase its degradation (83).  
1.4.1.3.2 Extra-renal 
 
Recent experiments on FGF23 knockout mice revealed that FGF23 acts in a 
systemic manner rather than in an autocrine/paracrine manner. Target organs 
of FGF23 are tissues that express FGFR and klotho like parathyroid glands and 
brain or tissues that only express FGFR like thymus, spleen, or bones (54). The 
parathyroid gland expresses FGF receptors and klotho, thus it is regarded as 
FGF23 target tissue. The effect of FGF23 on parathyroid gland remains 
controversial. Some studies suggest that FGF23 suppresses the PTH secretion 
by the creation of PTH - FGF23 feedback loop (increased PTH → increased 
FGF23 → decreased PTH), but other studies suggest that FGF23 stimulates 
the production of PTH (84, 85). The effects of FGF23 on other extra-renal 
organs  remain uncertain (Fig. 4) (54).  
13 
 
Fig. 4. Renal and extra-renal functions of FGF23. 
A. FGF23 activates FGFR/klotho complexes in the distal tubules (DT) leading to 
predominant events in the proximal convoluted tubules (PCT).  
B. Extra renal targets of FGF23 including heart, brain, thymus, spleen and bone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1.4  FGF23 regulation 
 
The regulation of FGF23 is complex and not completely understood. FGF23 
regulators include PTH, 1,25(OH)2D3, secreted klotho, glucocorticoids, calcium 
and phosphate. 1,25(OH)2D3 is the main regulator of FGF23. It stimulates 
FGF23 production thereby creating a negative feedback loop regulating 
1,25(OH)2D3 production (increased 1,25(OH)2D3 level → stimulate FGF23 → 
decreased 1,25(OH)2D3) (86). In humans, the role of phosphate in FGF23 
remains conflicting, with some studies demonstrating that high phosphate diet is 
associated with an increase in FGF23 serum level, while other studies 
demonstrate a negative correlation between FGF23 and oral Pi (87, 88). PTH 
stimulates the synthesis and production of FGF23 from the bones (89). There 
are no in vitro data to date to support a direct effect of klotho on FGF23 
production, but the results from in vivo experiments suggest that klotho 
influences the FGF23 production in bones. This finding is based on the fact that 
both primary (genetic deletion or mutation) and secondary (CKD) klotho 
deficiencies are associated with an increase in the FGF23 level (90). 
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Fig. 5. Phosphorus exchange. 
The body phosphate homeostasis is determined by modulation of the intestinal 
uptake of dietary phosphate, renal phosphate excretion and the exchange of 
phosphate between extracellular and bone storage pools. 
 
Other FGF23 regulators include PHEX, and DMP-1. The exact mechanism(s) 
through which DMP1 and PHEX regulate FGF23 are yet to be determined. 
However, recent studies demonstrate the absence of either PHEX or DMP-1 
associated with an increase in FGF23 level in the osteocyte and in the 
circulation, leading to an increased phosphate excretion by the kidney (58, 91, 
92).  
1.4.1.5 FGF23 and phosphate homeostasis 
1.4.1.5.1 Phosphate homeostasis   
 
Phosphorus is a common anion, distributed ubiquitously throughout the body. It 
plays an important role in a variety of biological processes, such as cell 
signalling, nucleic acid synthesis, energy homeostasis, maintenance of acid–
based balance, formation of lipid bilayers, and bone formation. 80% - 85% of 
the total body phosphorus is present in the bone; the remaining is present in 
soft tissue (14%) and extracellular fluid (1%). (Fig. 5) (93, 94). 
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1.4.1.5.2 Phosphate absorption 
 
Intestinal phosphate absorption plays a more significant role in phosphate 
homeostasis than was previously recognized. Phosphorus is absorbed from the 
intestine, predominantly in the jejunum, through passive and transcellular 
pathways. Passive pathway (also known as paracellular pathway) is dependent 
on the phosphate gradient in the gut, while the transcellular mechanism is 
mediated by sodium-dependent phosphate co-transporters (NaPi-IIb) and 
controlled by vitamin D3 (VD3) (95).  
At normal physiological state, 90% of serum phosphate is filtered at the level of 
the glomerulus, 60% - 70% of the filtered phosphate is reabsorbed in the apical 
membrane of proximal tubule and 20% - 30% is reabsorbed beyond the 
proximal tubule. Phosphate is reabsorbed in the renal proximal tubule through 
NaPi-II. Three types of NaPi have been identified (95, 96). 
Type 1 NaPi: belongs to the SLC17 family and is expressed in the kidney, liver, 
brain and parathyroid gland. In the kidney, it is expressed in the proximal 
tubules and to a lesser extent in the distal tubules. NaPi-1 is not thought to play 
an important role in renal phosphate reabsorption, since its expression in NaPi-
IIa knockout mice fails to compensate for hypophosphatemia (97). 
Type 2 NaPi: belongs to the SLC34 family. Three isoforms of type 2 NaPi 
transports have been identified: 
• NaPi-IIa is expressed mainly in the brush border membrane (BBM) of the 
proximal tubule. The results of the previous studies demonstrate that 
NaPi-IIa is a key mediator of Pi reabsorption in the renal proximal 
tubules. It mediates 70% of total renal phosphate reabsorption and it is 
under the control of PTH, FGF23 and dietary phosphate (98-100). 
• NaPi-IIb is primarily expressed in the small intestine. It plays a crucial 
role in intestinal phosphate absorption and it is under the control of 
1,25(OH)2D3 and dietary phosphate (101-103). 
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• NaPi-IIc is expressed primarily in the proximal tubule (104) and mediates 
approximately 30% of renal phosphate reabsorption. It is regulated by 
dietary phosphate, magnesium, metabolic acidosis, and FGF23 (105, 
106). 
Type 3 NaPi: is a member of SLC20 family. Type III transporters, specifically 
PiT1 and PiT2; have recently been shown to mediate phosphate transport. Type 
III NaPi transporters are expressed ubiquitously in several species. It is now 
clear that PiT2 is present at the renal BBM and PiT1 at the intestinal BBM and 
that these proteins are controlled by dietary phosphate load and FGF23 (97, 
104, 107).  
1.4.1.5.3 Phosphotoxicity  
 
Elevated serum phosphate level has emerged recently as a risk factor for the 
vascular calcification and cardiovascular disease in CKD as well as in general 
population. High phosphate level in the blood can lead to ectopic calcification 
and arteriosclerosis, COPD, CKD and loss of hearing in a person with normal 
renal function (108).  Moreover, Pi-lowering therapy has been demonstrated to 
improve mortality and clinical outcome in patients with CKD. Recent in vivo 
studies provide evidence that phosphate toxicity accelerates the aging process 
in mammals (56), an effect which may be in part due to vascular calcification 
(109). The role of phosphate in vascular calcification has come under intense 
investigation (110). Therefore, maintaining a normal serum phosphate 
concentration is very important to prevent calcification and prolong survival 
(111, 112). 
1.4.1.5.4 The effects of FGF23 on phosphate homeostasis  
 
Phosphate homeostasis is a complex process that under tight hormonal control. 
It was previously thought that 1,25(OH)2D3 and PTH are the sole regulators of 
inorganic phosphate (Pi) homeostasis, but recent studies have identified several 
new factors that also play a role in the regulation of phosphate homeostasis 
among which a mention can be made of FGF-23, FRP-4, FGF7, and MEPE. 
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Several studies demonstrate that FGF23 remains to be the key regulator of 
phosphate homeostasis (113-116). Dietary phosphate and age have also been 
found to influence plasma Pi concentrations. Studies on animals and humans 
demonstrate that aging process is associated with a reduction in both the renal 
and intestinal expression of type II NaPi co-transporter (117). FGF23 inhibits the 
phosphate reabsorption more directly through inhibition of NaPi-IIa and NaPi-IIc 
expression in the proximal renal tubule. FGF23 regulates the serum level of 
phosphate and 1,25(OH)2D3. PTH and 1,25(OH)2D3 stimulates the release of 
FGF23 from the bones (Fig. 6) (118-121).  
PTH and 1,25(OH)2D3 are two additional hormones which play an important role 
in phosphate homeostasis. PTH down-regulates the expression of NaPi-IIa and 
NaPi-IIc in BBM of proximal tubule and causes phosphaturia similar to FGF23, 
but unlike the FGF23, the PTH increases the production of 1,25(OH)2D3, which 
then acts on the intestine to enhance the absorption of calcium and phosphate. 
Thus, PTH and FGF23 have opposing effects on 1,25(OH)2D3 production.  
FGF23 inhibits PTH; therefore, it abolishes the activation of CYP27B1 by PTH.  
At the same time, 1,25(OH)2D3 inhibits the PTH production (115, 122).  
FGF23 is recognized as a key regulator of phosphate homeostasis acting 
independently of the two main endocrine factors, PTH and calcitriol.  In addition, 
PTH and calcitriol synthesis are also regulated by FGF23. Thus, FGF23 
regulates the phosphate homeostasis directly through its effects on the renal 
phosphate transporters or indirectly through the regulation of PTH and calcitriol, 
(Fig. 6) (122-124). 
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Fig. 6. Feedbacks regulating serum phosphate level. 
Inorganic phosphate is tightly regulated by the three organs depicted here, parathyroid, 
bone, and kidney, interacting with one another through three feedback loops. 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1.6  The effects of FGF23 on 1,25(OH)2D3 
1.4.1.6.1 Vitamin D3 (VD3) metabolism  
  
Vitamin D is a group of fat-soluble vitamins, which is plays a key role in 
controlling the renal excretion of both calcium and phosphorus. The two major 
forms of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol). VD3 synthesizes in the skin from 7-dehydrocholesterol through 
a photochemical process, or it can be obtained from various dietary sources 
such as fortified dairy products and fish oils. Cholecalciferol is an inactive form 
and it is converted to its active form via two hydroxylation steps. The first step 
occurs in the liver, where the VD3 is converted into 25-hydroxycholecalciferol 
25(OH)D by 25-hydroxylase. The second step occurs in the kidney, where 
25(OH)D is converted to 1,25(OH)2D3 by the enzyme 1α-hydroxylase, which is 
expressed primarily in the renal proximal tubule (125-128).  
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FGF23 is regarded as a 1,25(OH)2D3 counter regulatory hormone. It down-
regulates the renal 1α-hydroxylase and up-regulates 25 hydroxyvitamin D-
24hydroxylase, therefore leading to decreased formation and increased 
catabolism of 1,25(OH)2D3 (129, 130). 
1.4.1.6.2 Role of 1,25(OH)2D3 in phosphate and calcium metabolism 
 
1,25(OH)2D3 is a powerful stimulator of intestinal and renal phosphate and 
calcium transport. Moreover, it is an important regulator of PTH. Several studies 
have demonstrated that 1,25(OH)2D3 influences calcium and phosphate 
homeostasis by affecting their metabolism and absorption in the intestines, 
kidneys and bones. Biologic effects of VD3 result largely from binding of  VD3 to 
its vitamin D receptor (VDR), which is found almost in all tissues (131).   
Serum calcium level is very tightly regulated by the calcium-sensing receptors 
(CaSR), which are directly regulated by PTH and calcitriol levels. The exact role 
of FGF23 in Ca2+ homeostasis is not completely understood yet. 
High 1,25(OH)2D3 serum level leads to increase the intestinal Ca2+ absorption, 
and reduce the renal Ca2+ excretion. The major action of 1,25(OH)2D3  on the 
small intestine is the stimulation of calcium absorption; a process that occurs 
via active and passive mechanisms (132, 133). The 1,25(OH)2D3 regulates the 
serum phosphate level directly through an increase in the intestinal phosphate 
absorption by enhancing the expression of NaPi-IIb (134) and also indirectly by 
increasing its renal reabsorption through the suppression of PTH (135-137). 
1,25(OH)2D3 has also been found to affect the expression of NaPi-IIa in the 
renal cortex (137). Several studies have demonstrated that vitamin D3 may 
exacerbate the vascular calcification by direct and indirect mechanisms, direct 
by an increase at the calcium and phosphorus blood level or indirect through 
transforming the VSMCs into osteoblastic-like cells, since it stimulates the 
calcium flux and modulates the expression of several proteins associated with 
calcification into VSMCs (138).  
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2 Aims of the study 
 
As aforementioned, GSK-3 has been implicated in different physiological 
functions such as metabolism, cell cycle, gene expression and development in 
various biological systems (139). Aberrant GSK-3 levels are associated with 
several chronic disorders including inflammatory conditions (139), apoptosis 
(26), vascular calcification (140) and regulation of many age-related pathways 
(141). GSK-3 is considered as an important therapeutic target in these 
pathologies. Lithium is a known GSK-3 inhibitor, which is used widely for the 
treatment of mood disorders. Several studies have now suggested that lithium 
exerts its effects through GSK-3 inhibition (142, 143). 
Recent observations have revealed that renal klotho expression is markedly 
down-regulated by dehydration (144, 145). Lithium impairs the urinary 
concentrating ability of the kidney resulting in NDI, a disorder characterized by 
unresponsiveness of the kidneys to the action of ADH, leading to polyuria, 
sodium diuresis, and mild dehydration (18). According to these findings,  lithium 
treatment could affect the renal expression of klotho, which is an important 
FGF23 co-receptor (146).   
FGF23 is a powerful inhibitor of ageing, whose lack can lead to premature 
appearance of a wide variety of age-related disorders. Recent studies 
demonstrate a correlation between antidepressant treatments and FGF 
expression in the cerebral cortex (48). The relationship between lithium and 
FGF23 remains to be elucidated. 
The specific aims of this project are: 
• To explore the effect of lithium on the klotho / FGF23 hormonal axis. 
• To explore whether lithium treatment influence 1,25(OH)2D3 formation and 
renal phosphate and calcium excretion.  
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3 Materials and methods  
3.1 Materials 
3.1.1 Chart of materials and instruments  
 
Sartorius, Göttingen, Germany  Balance  
Eppendorf, Hamburg, Germany  Centrifuge, 5417 R/5415C 
Hettich, Tuttlingen, Germany  Centrifuge, Rotana 469 R 
Sysmex, Norsted, Germany  Clinical chemistry analyzer,  
    FUJI FDC 3500i 
Eppendorf, Hamburg, Germany  Electronic pipette, Multipette 
    Stream         
Eppendorf, Hamburg, Germany  Flame photometer, AFM 5051 
Eppendorf, Hamburg, Germany  Flame photometer, ELEX 6361 
Thermo Fisher Scientific Inc., MA USA  ELISA reader, Multiscan Ex 
Hirschmann laborgerate, Eberstadt, 
Germany 
 Heparinized capillaries 
Memert, Schwabach, Germany  Hot air oven 
Techniplast,  Hohenpeißenberg, Germany  Metabolic cages 
Brand GmbH, Wertheim, Germany  Micro-Haematokrit capillary 
Eppendorf, Hamburg, Germany  Multichannel pipette 
Eppendorf, Hamburg, Germany  Multi reaction tubes 
Thermo Fisher Scientific Inc., MA USA  Photometer, GENESYS 6 
Eppendorf, Hamburg, Germany   Pipette 
Hirschmann Laborgerate, Eberstadt, 
Germany 
 Pipetting aid 
Greiner Bio-one, Frickenhausen, Germany  Petri dishes 
Carl Roth, Karlsruhe, Germany  Pipette tips 
IKA, Staufen, Germany  Shaker VIBRAX VXR 
Savant Life Sciences, Bath, UK  SpeedVac SVC 100 
Greiner Bio-One, Frickenhausen, Germany  Sterile PS-tube 4.5 ml  
Braun, Melsungen, Germany  Syringes, Omnifix-H, 1ml 
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Carl Roth, Karlsruhe, Germany  Timer 
   Brand GmbH, Wertheim, Germany  UV-cuvettes 8.5mm 
 Labnet Abimed, Langenfeld, Germany  Vortex VX100 
 Julabo Labortechnik, Seelbach, Germany  Water bath SW-20C 
 Greiner Bio-one, Frickenhausen, Germany  6-well-plates  
 Greiner Bio-one, Frickenhausen, Germany  96-well-plates 
 Sigma-Aldrich, Hannover, Germany  Serological pipettes (5ml, 
10ml) 
Thermo Fisher Scientific Inc., MA USA Cryotube (Nunc CryoLine 
System) 
  
  
3.1.2 Chemicals 
 
 Sigma, Schnelldorf, Germany  Calcitriol 
 Carl Roth, Karlsruhe, Germany  Chloroform 
 Ampuwa, Niefern, Germany  Destilled water                       
 Carl Roth, Karlsruhe, Germany  Diethylether 
 Promega, Mannheim, Germany  DEPC water 
 GIBCO, Carlsbad, Germany  DMEM high glucose 
 Promega, Mannheim, Germany  dNTP mix 
 GIBCO, Carlsbad, Germany  EDTA-trypsin(0.25%) 
 Carl Roth, Karlsruhe, Germany  Ethanol absolute (99%) 
 Peprotech/Tebu, Carlsbad, Germany  Foetal Bovine Serum (FBS)    
    GIBCO 
Promega, Mannheim, Germany  GoTaq® qPCR Master Mix 
Sigma, Taufkirchen, Germany  HEPES 
Curamed Pharma GmbH, Karlsruhe, 
Germany 
 
 Isoflurane 
   
23 
 
Complete mini, Roche, Mannheim, 
Germany 
Inhibitor coctail tablet   
  Calbiochem, Merck GmbH, Germany  LiCl 
  Linde, Wiesbaden, Germany  Nitrogen liquide 
  Fresenius Kabi Bad Homburg, Germany  Normal saline 0.9% 
  GIBCO, Carlsbad, Germany  PBS 
  GIBCO, Carlsbad, Germany  Penicillin-Streptomycin 
  PEQLAB Biotechnologie GMBH, 
        Erlangen, Germany 
 peqGOLD TriFast 
  Complete mini, Roche,Mannheim, 
        Germany 
 Phosphatase/Protease 
  PBS tablets, Invitrogen, Karslruhe,  
        Germany 
 Phosphate-buffered saline 
  Sigma, Taufkirchen, Germany  2-Propanol (Isopropanol) 
  Invitrogen, Darmstadt Germany  Primers 
  Invitrogen, Darmstadt Germany  Random Hexamers 
  Cell Signalin, Frankfurt, Germany  RIPA lysis buffer 
  Sigma-Aldrich, Hannover, Germany  Sodium chloride 
  Invitrogen, Darmstadt Germany  SuperScript III reverse 
  Sigma, Taufkirchen, Germany Trypan blue solution 0,4% 
  Sigma, Taufkirchen, Germany 
 
Tween-20 
3.1.3 Kits  
3.1.3.1 Animal study  
 
• Mouse C-terminal FGF23 ELISA kit (Immutopics International, San 
Clemente, CA, USA). 
• Calcitriol kit (IDS, Boldon, UK).  
• Plasma ADH ELISA kit (Phoenix Pharmaceuticals, Germany). 
• Creatinine kit for plasma – creatinine PAP (Labor technik, Berlin, 
Germany). 
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• Creatinine kit for urine – creatinine Jaffe (Labor technik, Berlin,Germany). 
• Inorganic phosphate (Roche Diagnostics, Mannheim, Germany). 
3.1.3.2 Human study  
 
• Human serum C-terminal FGF23 ELISA kit (Immutopics International, 
San Clemente, CA, USA). 
• Calcitriol kit (IDS, Boldon, UK).  
• Inorganic phosphate (Roche Diagnostics, Mannheim, Germany). 
• Serum soluble α-klotho level (IBL, Minneapolis, USA). 
3.1.4 Animal diet  
 
Standard diet containing 1% Calcium, 0.7% phosphorus and 1,000 IU vitamin 
D3/kg (Ssniff, Soest, Germany). 
3.1.5 Software  
 
• Computerized data acquisition      Springs, USA 
• Chart version.4.2                          Axon Instruments, California, USA 
• Data link version 1.0.0                  Herbert & Scheneider Software & CAM,                                         
                                                              Germany   
• GraphPad Instat version 3.05        GraphPad Software Inc., San Diego, 
                                                              USA 
• Magellan version 3.11                  Tecan GmbH, Crailsheim, Germany 
• Sigma plot version 7.0                  Systat Software Inc., Erkrath, Germany 
• Quantity One software                  Bio-Rad, Munich, Germany. 
• Endnote VII                                  Thomson Reuters, CA, USA 
 
 
 
25 
 
3.1.6 Experimental animals 
 
All animal experiments were conducted according to the German law for the 
welfare of animals and were approved by local authorities. The experiments 
were performed on female C57Bl/6 mice at 10 week-old. The mice had free 
access to water and control food containing 1% calcium, 0.7% phosphorus and 
1,000 IU vitamin D3/kg. 
3.1.7 Metabolic cages 
 
For evaluation of renal excretion, the mice were placed individually in metabolic 
cages from day 11–14 of lithium treatment for 24 hours of urine collection to 
determine the excretion of urine, and to collect uncontaminated samples of 
urine.  
3.1.8 Patient recruitment 
 
The patients were recruited for this study in the Department of Psychiatry and 
Psychotherapy, Charité Campus Mitte, Berlin. 
A total of 95 acute depressive patients (38 males, 57 females, age 48 ± 14 
years) were recruited for this study. Inclusion criteria were, unipolar major 
depression, age older than 18 years, indication for an antidepressant 
pharmacotherapy, insufficient response to an adequate antidepressant 
pretreatment and clinical indication for lithium augmentation, Hamilton 
Depression Scale (HAMD-17) score of 12 or greater, and written informed 
consent. The diagnosis was confirmed on the basis of the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental Disorders. All patients 
received individual doses of lithium carbonate adjusted individually for each 
patient targeting lithium serum-level more than 0.4 mmol/L (147). Blood was 
drawn from patients first before lithium augmentation and then after 4 weeks 
following the medication with lithium. Detailed clinical data of the patients have 
already been published (145). 
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3.2 Methods 
3.2.1 Murine experiments  
3.2.1.1 Determination of serum and plasma concentrations  
 
To collect blood specimens, animals were lightly anesthetized with diethylether 
and about 50 - 200 µl of blood was withdrawn into heparinized capillaries by 
puncturing the retro-orbital plexus. Serum C-terminal FGF23, ADH and serum 
1,25(OH)2D3 concentrations were measured by ELISA. The serum phosphate 
and total Ca2+ concentrations were measured by a photometric method. The 
free calcium concentration was analyzed by a blood gas analyzer in heparinized 
plasma samples. 
3.2.1.2 Measurement of urinary calcium and phosphate concentrations 
 
For evaluation of the renal excretion, the mice were placed individually in 
metabolic cages from day 11–14 of lithium treatment for 24h. The mice had free 
access to drinking water and food. They were allowed 2-day habituation period 
when food, water intake, urinary flow rate, urinary excretion, and body weight 
were recorded every day to ascertain that the mice were adapted to the new 
environment. Subsequently, 24 hours collection of urine was performed to 
obtain the urinary parameters. To assure the quantitative urine collection, the 
metabolic cages were siliconized and the urine was collected under water-
saturated oil (148). The urinary phosphate concentration was determined 
colorimetrically utilizing a commercial diagnostic kit. The urinary calcium was 
measured by flame photometry. 
3.2.1.3 Western blotting   
 
To analyze the klotho and NaPi-IIa protein abundance and GSK-3 
phosphorylation in renal tissue, the kidneys were removed and immediately 
snap-frozen in liquid nitrogen. After homogenization in lysis buffer (54.6 mM 
HEPES; 2.69 mM Na4P2O7; 360 mM NaCl; 10 % (v/v) glycerol; 1 % (v/v) NP40 
or RIPA lysis buffer containing phosphatase and protease inhibitor cocktail 
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tablet, the samples were incubated on ice for 30 min and then centrifuged at 
14,000 rpm and 4 °C for 20 min. The supernatant was removed and used for 
Western blotting. The total protein (80 µg) was separated by SDS PAGE, 
thereafter transferred to nitrocellulose membranes and blocked in 5 % non-fat 
milk/Tris-buffered saline/Tween-20 (TBST) at room temperature for 1h. The 
membranes were probed overnight at 4 °C with polyclonal rat anti-klotho 
antibody (1:1,000 in 5 % fat-free milk in TBST), with rabbit anti-NaPi-IIa 
antibody (149); 1:3,000 in TBST with 5 % BSA), or with rabbit anti-phospho-
GSK-3ß (1:1,000 in TBST supplemented with 5 % BSA). After incubation with 
horseradish peroxides-conjugated anti-rat or anti-rabbit secondary antibodies 
(1:2,000) for 1 hour at room temperature, the bands were visualized with 
enhanced chemiluminescence reagents. The membranes were also probed 
with GAPDH antibody as loading control. The densitometry analysis was 
performed using Quantity One software. 
3.2.1.4 FGF23 transcripts in UMR106 cells 
 
The UMR106 rat osteosarcoma cells were cultured in DMEM high glucose 
medium supplemented with 10 % FCS and 1 % penicillin/streptomycin under 
standard conditions. The cells were pretreated with 100 nM calcitriol to induce 
the FGF23 expression (150). After 24 hours, the cells were in addition treated 
either with lithium (2 mM) for another 24 hours or with [Arg8]-vasopressin 
acetate salt (50 nM) for another 12 hours, or with recombinant human klotho 
protein (30 ng/ml) for another 12 hours, or were left untreated. Then, the entire 
RNA was isolated with TriFast RNA extraction reagent based on a chloroform 
extraction protocol. mRNA was transcribed with SuperScript III reverse 
transcriptase using an oligodT Q2 primer. Quantitative reverse-transcription 
polymerase chain reaction (RT-PCR) was performed on a Bio-Rad iCycler iQTM 
real-time PCR detection system using the following primers: 
Tbp (TATA box-binding protein) 
Forward (5′-3′): ACTCCTGCCACACCAGCC 
Reverse (5′-3′): GGTCAAGTTTACAGCCAAGATTCA 
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Fgf23 
Forward (5′-3′): TGGCCATGTAGACGGAACAC 
Reverse (5′-3′): GGCCCCTATTATCACTACGGAG 
The final volume of the PCR reaction mixture was 20 µl and contained 2 µl 
cDNA, 1 µMoL each primer, 10 µl GoTaq qPCR master mix, and sterile water 
up to 20 µl. The qPCR conditions were 95 °C for 3 min, followed by 40 cycles of 
95 °C for 10 s, and 58 °C for 10 s. The calculated mRNA expression levels were 
normalized to the expression levels of Tbp of the same cDNA sample. Relative 
quantification of gene expression was performed using the ∆∆ct method. 
3.2.1.5 Statistical analysis  
 
Data are provided as means ± SEM; n represents the number of independent 
experiments. All data were tested for significance using unpaired Student’s t-
test unless otherwise stated. Only results with p <0.05 were considered 
statistically significant. 
3.2.2 Human experiments  
3.2.2.1 Determination of serum concentration 
 
ELISA kits were employed to determine the serum concentrations of FGF23, 
klotho and 1,25(OH)2D3 according to the manufacturer’s instructions. The serum 
phosphate and Ca2+ concentrations were measured by a photometric method.   
3.2.2.2 Statistical analysis  
 
Data are provided as means ± SEM, n; represents the number of independent 
experiments. All data were tested for significance using unpaired Student’s t-
test. Only results with p < 0.05 were considered statistically significant. 
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4 Results 
 
Lithium has been demonstrated as a GSK-3 inhibitor. It is widely used for the 
treatment of mood disorders (28, 29). Several studies demonstrate that lithium 
inhibits GSK-3 directly by competing for an Mg2+ binding site or indirectly by 
increasing the inhibitory serine-phosphorylation of GSK-3 (26). Lithium 
treatment interferes with renal effects of ADH, thus causing NDI, which is a 
clinical syndrome characterised by polyuria, sodium diuresis, and mild 
dehydration (18). Recent observations revealed that renal klotho expression is 
markedly downregulated by dehydration (144, 145). Klotho is required as co-
receptor for mediating the phosphaturic actions of FGF23 (118, 151).  
In this chapter, we investigate the effect of lithium on the FGF23 hormonal axis 
using a murine model and blood samples from acute depressive patients. 
4.1 Murine model  
  
4.1.1 The effect of lithium on renal GSK-3 phosphorylation in 
the murine model 
 
In order to demonstrate the effect of lithium on renal GSK-3 phosphorylation, 10 
week-old female C57BL/6 mice were subcutaneously injected with 200 mg/Kg 
LiCl and vehicle (NaCl) for 14 days. The kidneys were subsequently removed 
and renal GSK-3 phosphorylation was determined by Western blotting. As 
illustrated in Fig. 7, lithium treatment was followed by a significant increase in 
GSK-3 phosphorylation.  
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Fig. 7. Renal GSK-3 phosphorylation.  
Original Western blot showing the protein abundance of phosphorylated GSK-3 and GAPDH 
(upper panel) and arithmetic means ± SEM (n =4/group) of the phosphorylated GSK-3 over 
GAPDH protein abundance ratio (lower panel) in renal tissue from sham- (white bar) and 
lithium treated (black bar) wild type mice. *p <0.05 indicates a significant difference from 
untreated mice. 
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 Fig. 8. Serum ADH level. 
Arithmetic means ± SEM of serum ADH levels (n =4/group) in sham-(white bar) and lithium-
treated (black bar) wild type mice. *p <0.05 indicates a significant difference from untreated 
mice. 
4.1.2 The effect of lithium on ADH serum level in lithium treated 
mice  
 
Lithium treatment is one of the common causes of acquired NDI, which is a 
clinical syndrome characterized by reducing the renal responsiveness to ADH 
leading to an increase in water and sodium diuresis; effects which can result in 
mild dehydration (18). This finding could suggest that lithium treatment may 
affect the renal klotho expression. 
To clarify whether lithium could result in a state of dehydration, 10 week-old 
female C57BL/6 mice were subcutaneously injected with 200 mg/Kg LiCl and 
vehicle (NaCl) for 14 days. Whole blood samples were collected, the serum was 
separated and the serum ADH was measured using ELISA method. As 
illustrated in Fig. 8, lithium treatment was followed by an increase in ADH serum 
level.  
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 Fig. 9. Body weight. 
Arithmetic means ±SEM of body weight (n =6) in sham- (blue bar) and lithium-treated (pink 
bar) wild type mice. 
 
4.1.3 Body weight in lithium treated mice 
 
Body weight in mice treated with LiCl and NaCl (control group) was monitored 
throughout the treatment duration (14 days). As shown in Fig. 9, lithium 
treatment did not influence the body weight.  
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Fig. 10. Renal klotho expression. 
Original Western blot showing renal expression of klotho and GAPDH (upper panel) and 
arithmetic means ± SEM (n =4/group) of the klotho over GAPDH protein abundance ratio 
(lower panel) in renal tissue from sham- (white bar) and lithium-treated (black bar) wild type 
mice. *p <0.05 indicates a significant difference from untreated mice.  
4.1.4 The effect of lithium on renal klotho expression in lithium 
treated mice  
 
Recent observations revealed that renal klotho expression is markedly down-
regulated by dehydration (142, 143). To elucidate the effects of lithium 
treatment on the renal klotho expression, kidneys of the mice were removed 14 
days after treatment with NaCl or with LiCl only. The renal klotho protein 
abundance was determined by Western blotting. As illustrated in Fig. 10, lithium 
treatment was followed by a strong and statistically significant decrease in the 
renal klotho protein abundance.  
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 Fig. 11. Serum FGF23 level.   
Arithmetic means ± SEM (n =10/group) of serum FGF23 levels in sham- (white bar) and 
lithium- treated (black bar) wild type mice. ***p <0.001 indicates a significant difference from 
untreated mice. 
4.1.5 The effect of lithium on FGF23  
4.1.5.1 FGF23 serum level  
 
Several studies have identified klotho as a FGF23 co-receptor. Its forms 
complexes with FGFRs and increases their affinity to FGF23 (152). The 
importance of klotho in FGF23 signaling is illustrated by both human and animal 
studies, where loss of klotho results in an end-organ resistance to FGF23 (54, 
153). In order to explore whether lithium treatment regulates FGF23 secretion, 
the serum FGF23 level was measured in sham and lithium treated mice. Fig. 11 
shows that lithium treatment was followed by a dramatic and statistically 
significant increase in the serum FGF23 compared to the control group.  
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4.1.5.2 FGF23 transcript level in UMR106 cells treated with lithium 
 
As shown in Fig.7, 8, 10 and 11, lithium treatment is found to decrease both the 
GSK-3 activity (inhibitory phosphorylation) and renal klotho protein abundance 
and increase the ADH and FGF23 serum level. An increase in serum FGF23 
level following lithium treatment could be due to the influence of ADH or klotho 
on FGF23 transcription level. 
To investigate this conjecture, UMR106 osteoblast-like cells were treated with 
[Arg8]-vasopressin (50 nM) and FGF23 transcript levels were determined by 
qRT-PCR. As a result, [Arg8]-vasopressin significantly decreased the FGF23 
transcript levels (0.00522±0.00100 arb. units (n =15)) compared to untreated 
cells (0.01157±0.00215 arb. units (n =15); p <0.05, u test). This result indicates 
that ADH is unlikely to increase the FGF23 serum level in the lithium treated 
mice.  
Next experiments explored whether klotho protein influences the FGF23 
transcription in UMR106 osteoblast-like cells. The FGF23 transcript level was 
0.01063±0.00341 arb. units (n =15) in klotho protein treated cells (30 ng/ml) and 
(0.00708±0.00187 arb. units (n =15) in untreated cells. Thus, klotho protein did 
not significantly influence the FGF23 expression. 
However, exposure of UMR106 osteoblast-like cells to (2 mM) LiCl stimulated 
FGF23 expression as revealed by quantitative RT- PCR. The FGF23 transcript 
level approached 0.00769±0.00098 arb. units (n =15) in untreated and 
0.01245±0.00208 arb. units (n =15) in lithium-treated UMR106 cells (p <0.001, 
u test).  
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Fig. 12. Serum 1,25(OH)2D3 Level. 
Arithmetic means ± SEM (n =4–5/group) of serum 1,25(OH)2D3 levels in sham- (white bar) 
and lithium-treated (black bar) wild type mice. **p <0.01 indicates a significant difference 
from the untreated mice.  
4.1.6 1,25(OH)2D3 serum level 
 
Experimental studies on FGF23 and klotho knockout have demonstrated that 
FGF23 and klotho act in concert to down-regulate the expression of 1α-
hydroxylase, which is the key enzyme in the synthesis of 1,25(OH)2D3 (63). In 
order to determine the effect of lithium treatment on 1,25(OH)2D3, blood-serum 
samples were collected from either lithium treated or control mice 14 days 
following lithium or NaCl treatment. ELISA was employed to measure the serum 
level of 1,25(OH)2D3. Fig. 12 reveals that lithium treatment does indeed 
decrease serum 1,25(OH)2D3 level.  
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Fig. 13. Serum phosphate level. 
Arithmetic means±SEM of serum phosphate concentration (n =10/group) in sham- 
(white bars) and lithium-treated (black bars) wild type mice. **p <0.01 indicates a 
significant difference from the sham-treated mice. 
 
4.1.7 The effects of lithium on phosphate metabolism  
 
FGF23 acts as a phosphaturic agent that reduces the serum inorganic 
phosphate (Pi) directly through the inhibition of renal NaPi-IIa transporter in the 
proximal tubule or indirectly through the suppression of calcitriol synthesis 
(118). The effects of 1,25(OH)2D3 include stimulation of intestinal and renal 
phosphate transport leading to a rise in the serum phosphate concentrations 
(136). Accordingly, serum and urinary phosphate concentrations were 
determined in control and lithium-treated mice.  
4.1.7.1 Serum phosphate level 
 
To elucidate whether serum phosphate level might be influenced by lithium 
treatment, the serum phosphate level was measured 14 days after treatment 
with or without LiCl by a photometric method. As shown in Fig. 13, lithium 
treatment significantly decreased the serum phosphate concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Fig. 14. urinary phosphate excretion. 
Arithmetic means±SEM of urinary phosphate excretion (n =6/group) in sham- (white bars) 
and lithium-treated (black bars) wild type mice. **p <0.01 indicates a significant difference 
from sham-treated mice.  
 
4.1.7.2 Urinary phosphate excretion  
 
Theoretically, the low serum phosphate level in lithium treated mice may be the 
consequence of an increase in the urinary phosphate excretion. Therefore, the 
mice were placed individually in metabolic cages from day 11-14 of lithium 
treatment. Urine was collected every 24h for 3 days and the urinary phosphate 
excretion was measured. As shown in Fig. 14, the lithium treatment significantly 
increases the urinary phosphate excretion.  
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Fig. 15. Renal expression of NaPi-IIa. 
Original Western blotting showing renal expression of NaPi-IIa (upper panel) and GAPDH 
(lower panel). 
 
4.1.7.3 Renal expression of NaPi-IIa 
 
In order to investigate whether the phosphaturia in lithium treated mice was 
paralleled by altered expression of the major renal phosphate transporters ( NaPi-
IIa ), Western blotting was employed to determine the renal expression of NaPi-
IIa. As shown in Fig. 15, lithium treatment did not significantly affect the total 
renal NaPi-IIa protein abundance. The densitometric analysis yielded a renal 
NaPi-IIa abundance of 0.55±0.04 arb. units (n =6) in sham-treated and 
0.59±0.06 arb. units (n =6) in lithium-treated animals.  
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 Fig. 16. Serum calcium level. 
Arithmetic means ± SEM of total serum calcium concentration (n =10/group) in the 
sham- (white bars) and lithium-treated (black bars) wild type mice. ***p <0.001 
indicates a significant difference from the sham-treated mice.  
4.1.8 The effects of lithium on calcium metabolism 
 
Serum calcium is found in three forms: 40% bound predominantly to albumin; 
10% is complexes with serum anions and 50% is ionized (154). The ionized 
serum calcium is the biologically active form of calcium and it constitutes a better 
indicator of the functional status of calcium metabolism than the total serum 
calcium. Since 1,25(OH)2D3 also leaves an impact on the renal calcium 
reabsorption, the serum and urinary calcium concentration were measured.  
4.1.8.1 Serum calcium level 
 
To explore the effects of lithium treatment on calcium metabolism, blood-serum 
samples were collected from either lithium treated or control mice 14 days 
following treatment and the total serum calcium level was measured by a 
photometric method. The ionized serum calcium concentration was analysed in 
whole blood samples by a blood gas analyser. As shown in Fig. 16, lithium 
treatment tends to decrease the total calcium level. However the plasma-free 
calcium levels were not different between sham-treated (0.93±0.03 mM, n =6) and 
lithium- treated mice (0.99±0.04 mM, n =5). 
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Fig. 17.Urinary calcium excretion.  
Arithmetic means±SEM of urinary calcium excretion (n =6/group) in the sham- (white bars) 
and lithium-treated (black bars) wild type mice. ***p <0.001 indicates a significant difference 
from the sham-treated mice.  
 
4.1.8.2 Urinary calcium excretion 
 
To measure the urinary calcium excretion, the mice were placed individually in 
metabolic cages for 3 days and urine was collected every 24h. The urinary 
calcium was measured by flame photometry. Fig. 17 demonstrates that the 
lithium treated mice suffer from an increase in the urinary calcium excretion 
compared to the control group. Calciuria in the lithium treated mice was not the 
simple consequence of hypercalcemia as their serum calcium level was not 
different from that of the control group.  
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In summary, lithium treatment significantly increased renal GSK3 
phosphorylation, enhanced serum ADH and FGF23 concentrations, 
downregulated renal klotho expression, stimulated renal calcium and phosphate 
excretion, and decreased serum 1,25(OH)2D3 and phosphate concentrations in 
lithium treated mice.  
Importantly, this murine study provides preliminary data indicating a novel 
powerful effect of lithium on the FGF23. Based on this result we want to 
investigate the effect of lithium treatment on FGF23 hormonal axis in acute 
depressive patients.  
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4.2 Human study  
 
Depression is a multifaceted disorder which has been associated with the risk to 
develop several medical disorders including cancer, dementia, diabetes, 
epilepsy and stroke (155). Since its introduction into modern psychiatry in the 
1950s and 1960s lithium has been mainly considered an effective maintenance 
treatment for bipolar disorders (156). Moreover, lithium has been identified as 
an important anti-suicidal and anti-inflammatory agent. Several studies have 
demonstrated that a small amount of lithium in drinking water reduces the rate 
of suicide and promotes the longevity in humans (5, 12, 14, 146-149), but the 
mechanism through which lithium exerts these effects is largely unknown. FGFs 
are one of the growth factors that involved in early brain development as well as 
maintenance and repair through adult life. Although the role of FGFs in 
psychiatric disorders has been growing relatively recently (157). 
Based on the results of murine study which showed a new effect of lithium on 
FGF23 hormonal axis following lithium treated, in this section we want to 
investigate the effect of lithium on the FGF23 hormonal axis using serum-blood 
samples from acute depressive patients.  
To this end, a total of 95 acute depressive patients (age 48 ± 14 years old) were 
recruited. All the patients received individual doses of lithium carbonate 
adjusted to their individual lithium serum levels. 
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 Fig. 18 Serum C-terminal FGF23. 
Arithmetic means ± SEM (n =95) of serum FGF23 levels prior to (white bars) and following 
(black bars) lithium augmentation. **p<0.01 indicates a significant difference from respective 
value prior to the treatment. 
 
 Serum C-terminal FGF23 level 4.2.1
 
To determine whether lithium treatment effects serum FGF23 levels in 
depressive patients, serum blood was taken from medicated patients before 
lithium augmentation and then after 4 weeks of medication with lithium. ELISA 
was used to measure serum FGF23 levels. Lithium treatment was followed by a 
marked increase at the serum FGF23 level of patients Fig. (18). 
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Fig. 19.Serum soluble α-klotho Level. 
Arithmetic means ± SEM (n =95) of serum klotho level prior to (white bars) and following 
(black bars) the lithium augmentation.  
 
 The serum soluble α- klotho level  4.2.2
 
In order to explore whether an increase in the FGF23 serum level is associated 
with altered serum klotho level in lithium treated depressive patients, the serum 
soluble α-klotho level was measured. As shown in Fig. 19, the serum klotho 
level tended to increase slightly in acute depressive patients following lithium 
augmentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Fig. 20. Serum 1,25(OH)2D3 level. 
Arithmetic means ± SEM (n =95) of serum 1,25(OH)2 D3 levels in the untreated (white 
bar) and the lithium treated (black bar) patients. **p<0.01 indicates a significant 
difference from respective value prior to the treatment. 
 
 The serum 1,25(OH)2D3 level  4.2.3
 
FGF23 down-regulates 1α-hydroxylase, the key enzyme in the production of 
1,25(OH)2D3 (129). The serum blood samples were isolated from the acutely 
depressive patients and the serum 1,25(OH)2D3 level was measured by ELISA. 
As shown in Fig. 20, the lithium treatment significantly decreased the serum 
1,25(OH)2D3 concentration in acute depressive patients. 
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Fig. 21. Serum phosphate level. 
Arithmetic means ± SEM (n =95) of serum phosphate concentration in the untreated (white 
bars) and lithium treated (black bars) patients. **p<0.01 indicates a significant difference 
from the respective value prior to the treatment. 
 
 The serum phosphate and calcium level  4.2.4
 
Decline in serum 1,25(OH)2D3 levels is expected to decrease both, the calcium 
and phosphate serum concentrations. Accordingly, the serum calcium and 
phosphate concentrations were determined before and 4 weeks after lithium 
augmentation in acute depressive patients. 
• Serum phosphate 
As illustrated in Fig. 21, lithium treatment significantly decreased the serum 
phosphate concentrations of patients. 
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Fig. 22. Serum calcium level. 
Arithmetic means ± SEM (n =95) of the serum calcium level in untreated (white 
bars) and lithium treated (black bars) patients.  
 
• Serum calcium level  
Fig. 22 demonstrates that serum Ca2+ concentration tends to decrease slightly 
following the lithium treatment in acute depressive patients, an effect, however 
not reaching statistical significance.  
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5 Discussion 
 
As aforementioned in the introduction, for more than 150 years lithium has been 
used as a therapeutic agent for treatment of manic-depressive disorders (18, 
44). However, the use of lithium is frequently complicated with an impaired 
responsiveness of the kidney to the action of ADH causing NDI, which is a 
clinical syndrome manifested by increased water and sodium diuresis, resulting 
in mild dehydration (18). Several lines of evidence have implicated that GSK-3 
plays a crucial role in the vasopressin-mediated urine concentration by the 
kidneys and suggested that decrease GSK-3 activity could be one of the initial 
targets through which lithium induce-NDI (32). 
Recent observations have revealed that renal klotho expression is markedly 
downregulated by dehydration (144, 145). Klotho is a transmembrane protein 
that acts as an obligatory coreceptor for FGF23. Several lines of evidence 
indicated that FGF23 and klotho knockout mice exhibit almost identical 
phenotypes that include abnormal mineral metabolism which characterized by 
increased blood Pi, Ca2+ and vitamin D3 levels (145, 158). Excessive 
1,25(OH)2D3 formation contributes to hyperphosphatemia which in turn fosters 
vascular calcification (118, 159). 
In this thesis I demonstrate, for the first time, a novel powerful effect of lithium 
on FGF23. Short term lithium treatment was found to produce a pronounced 
increase in FGF23 serum level, significantly decrease serum 1,25(OH)2D3 and 
phosphate concentration in mice and patients. It is noteworthy to point out that 
these effects were paralleled by a statistically significant decrease of renal 
klotho expression, and an increase in the renal phosphate excretion in lithium 
treated mice.  
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5.1 Murine study 
 
In order to investigate the effect of lithium on FGF23 hormonal axis, 10-week 
old female C57Bl/6 mice were treated with LiCl (n=6-10; 200 mg/kg 
subcutaneously) every 24h for 14-day period. In this thesis I provide preliminary 
data indicating that a 14-day lithium treatment significantly increased renal 
GSK-3 phosphorylation, enhanced serum ADH and FGF23 concentrations, 
downregulated renal klotho expression, stimulated renal calcium and phosphate 
excretion, and decreased serum 1,25(OH)2D3 and phosphate concentrations. 
The effect of lithium on serum FGF23 release may be in part due to GSK-3 
inhibition. Several experimental and clinical studies demonstrate that lithium 
exerts its effects through GSK-3 inhibition (157, 158). In the present murine 
study a 14-day lithium treatment is followed by a significant increase in GSK-3 
phosphorylation (inhibitory phosphorylation), suggesting that the 
neuroprotective effect of lithium might be at least partially mediated by an 
increase the FGF23 level. In other words, lithium treatment inhibits the GSK-3 
activity, which is a known effect of lithium. In animal and cell culture models, 
lithium has been shown to increase neuronal viability through a combination of 
mechanisms that include the inhibition of apoptosis, regulation of autophagy, 
increased mitochondrial function and synthesis of neurotrophic factors (160).  
As mentioned previously, lithium treatment is one of the drugs that can cause 
dehydration. It interferes with the renal effect of ADH causing NDI (161, 162). 
However, the underlying mechanism by which lithium causes NDI is not 
completely understood (161). There is strong evidence suggesting that GSK-3 
inactivation may account for the vasopressin-resistant polyuria of lithium-
induced NDI (18, 32). My observations suggest that the effect of lithium on 
FGF23 serum concentration may be in part due to polyuria and dehydration, 
reflected by increased ADH.  
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Dehydration has previously been shown to downregulate the renal klotho 
expression (162, 163). In the present study, a short-term administration of LiCl 
in C57Bl/6 mice was found to downregulate the renal membrane α-klotho 
expression, an effect which could be due to dehydration. FGF23 also increases 
the expression of renal klotho abundance (164). Membrane α-klotho is 
mandatory for FGF23 to activate its downstream signaling pathways. However 
there is growing evidence suggesting that FGF23 may stimulate its downstream 
signaling pathways in cells that lack or have little expression of membrane α-
klotho (54, 165, 166).  
Serum FGF23 levels are enhanced in gene-targeted mice lacking either SPAK 
(162) or OSR1 (163). Both SPAK and OSR1 stimulate renal tubular NaCl 
transporters, and thus lack of those kinases is expected to result in dehydration. 
However, according to the qRT-PCR results, ADH is unlikely to account for the 
enhanced FGF23 serum levels following lithium treatment, since the 
vasopressin analogue [Arg8]-vasopressin downregulates the FGF23 transcript 
levels in UMR106 osteoblast-like cells. 
Decreased klotho expression in lithium treated mice was expected to blunt the 
effects of FGF23 on 1,25(OH)2D3 formation. However, evidence from the 
murine experiments demonstrate that lithium treatment leads to decrease the 
1,25(OH)2D3 serums level in spite of the decrease in the expression of the renal 
klotho abundance. This result is consistent with a scenario which occurs in the 
early stage of CKD, in which an increase in FGF23 can attenuate phosphate 
retention and decrease 1,25(OH)2D3 formation despite a fall in renal α-klotho 
levels (167). Together, these lines of data could support the new hypothesis, 
that FGF23 can activate intracellular signaling pathways in cells that lack or 
have little expression of membrane α-klotho. 
1,25(OH)2D3 stimulates the release of FGF23 and the excessive 1,25(OH)2D3 
formation in klotho deficiency stimulates the FGF23 serum level (168). In the 
present murine study, a 14-day lithium treatment was found to increase the 
FGF23 serum level despite the observed decrease in 1,25(OH)2D3 serum 
concentrations, which were expected to result in a decrease of FGF23 release. 
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This finding implicated that 1,25(OH)2D3 does not account for the increase of 
FGF23 serum level following lithium treatment. FGF23 downregulates the renal 
25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase) and upregulates 25 
hydroxyvitamin D-24 hydroxylase, which are the enzymes responsible for the 
synthesis and degradation of 1,25(OH)2D3, respectively (118). The increase of 
FGF23 serum level following lithium treatment presumably accounts for the 
decrease of serum 1,25(OH)2D3 concentrations.  
1,25(OH)2D3 is a potent stimulator of both renal and intestinal phosphate 
transport (126). Increased FGF23 serum level following the lithium treatment in 
10 week-old female C57BL/6 mice was paralleled by hypophosphatemia and 
phosphaturia. Therefore, the hypophosphatemia could explain the phosphaturia 
in the lithium treated mice. This observation could be explained by the effect of 
FGF23 on 1,25(OH)2D3 metabolism and renal tubular phosphate transport. 
FGF23 has been found to increase the urinary phosphate excretion directly by 
reducing the expression of sodium/phosphate cotransporter type II (NaPi-II) and 
indirectly through reducing phosphate absorption in the gut by suppressing 1α-
hydroxylase activity (55). Therefore, an increased FGF23 release following 
lithium treatment is expected to generate phosphaturia and, thus, decreasing 
the serum phosphate concentration.  
According to the Western blot result in the murine experiments, lithium 
treatment did not reveal a significant decrease in the whole kidney NaPi-IIa 
protein abundance. The finding does, however, not rule out that the protein 
abundance in the apical cell membrane is decreased by lithium treatment. 
Alternatively, the lithium treatment affects the activity of the carrier.  
Furthermore, the present murine experiments demonstrate that the phosphaturia 
of the lithium treated mice is paralleled by increase in the urinary calcium 
excretion, which is not the simple consequence of hypercalcemia in the lithium 
treated mice, as their serum calcium level is not significantly different from that of 
the control group.  
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Lithium induce-hypercalcemia is a known side effect observed in a fraction of 
lithium-treated patients (169, 170). Lithium may increase the serum Ca2+ 
concentration by stimulating the PTH release, and it may decrease the serum 
Ca2+ concentration by lowering the 1,25(OH)2D3 serum concentrations (Fig. 6 
and 14). Thus, the eventual outcome may depend on the magnitude of the 
alterations in the PTH and 1,25(OH)2D3 release.  
Several lines of evidence from in vitro, clinical and epidemiological studies 
suggest that increased serum phosphate concentration predisposes to vascular 
calcification and eventually leads to an early appearance of age-related 
disorders and a decrease of life span (110, 112, 159). It would be interesting to 
speculate whether lithium treatment may attenuate the tissue calcification (171). 
The present observations may suggest that lithium is capable of counteracting 
vascular calcification, aging, and early death.  
Both klotho and FGF23 are essential regulators of aging. Lack of either klotho 
or FGF23 accelerates the development of several age-related disorders and 
eventually leads to early death (172). FGF23 deficiency elevates the serum 
phosphate, calcium, and 1,25(OH)2D3 levels, effects eventually leading to 
several disorders, such as vascular calcification, decrease in bone density, 
growth retardation, infertility, and a dramatic reduction of life span. Together, 
these lines of data indicate that lithium may counteract at least some of the 
multiple disorders observed in FGF23 deficiency.  
Circulating levels of FGF23 similarly increase in patients with renal insufficiency. 
Hyperphosphatemia is a risk factor for vascular calcification, cardiovascular 
disease and mortality in patients with renal insufficiency and FGF23 level is 
thought to increase as a compensatory mechanism to maintain normal 
phosphate balance in those patients (173, 174). Unlike renal insufficiency, 
lithium treatment lowers the serum phosphate concentration.  
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Taken together, these lines of evidence suggest that lithium treatment 
significantly increased renal GSK-3 phosphorylation, enhanced serum ADH and 
FGF23 concentrations, downregulated renal klotho expression, stimulated renal 
calcium and phosphate excretion, and decreased serum 1,25(OH)2D3 and 
phosphate concentrations.  This study provides preliminary data indicating that 
the effect of lithium on FGF23 may protect against vascular calcification and 
ultimately the appearance of age related disorders.  
5.2 Human study  
 
Lithium salt has been widely used as a mood stabilizing drug, particularly in the 
treatment of bipolar disorders. A recent study has further suggested that lithium 
may have a potential therapeutic effect against Alzheimer’s disease and other 
neurodegenerative disorders. However, the exact mechanism of lithium’s 
neuroprotective effect is largely unknown. Several studies in humans explain 
these neuroprotective effects by GSK-3 inhibition, increase of BDNF synthesis, 
increase expression of anti-apoptotic genes, inhibition of cellular oxidative 
stress, cortical thickening, increased grey matter density, and hippocampal 
enlargement (160).  
FGFs have been demonstrated as an essential factor for cell growth, 
differentiation and morphogenesis in the early stages of neural development. 
Moreover, a correlation between antidepressant treatments and FGF 
expression in the cerebral cortex and hippocampus has been observed (45). 
FGF23 is one of the most recently discovered FGFs, which maintain the 
phosphate and 1,25(OH)2D3 metabolism by regulating the renal expression of 
NaPi-IIa and vitamin D3 synthesis . 
Following the murine study which discloses an important effect of lithium on 
FGF23, I further investigated whether lithium treatment influences the FGF23 
serum level in lithium treated patients. To answer this question a total of 95 
acute depressive patients were recruited. Those patients were treated with 
lithium carbonate targeting a lithium serum level of more than 0.4 mmol/L. 
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Surprisingly, 4-weeks Lithium treatment was found to increase FGF23 serum 
levels without significantly modifying serum klotho concentrations and 
significantly decreased serum 1,25(OH)2D3 and phosphate concentrations 
without significantly modifying serum Ca2+ concentrations in those patients.  
At least in theory, the effect of lithium on FGF23 serum levels may in part be 
due to polyuria and dehydration. Serum FGF23 levels are enhanced in gene-
targeted mice lacking kinases involved in stimulation of renal tubular NaCl 
transport, and thus required for adequate renal salt and fluid reabsorption as 
well as hydration (175). FGF23 serum levels are further increased in renal 
insufficiency (167, 173).  
Contrary to the murine experiments, I observed that lithium treatment tends to 
increase the serum soluble α-klotho level in acute depressive patients, an 
effect, however not reaching the statistical significance. The functions of soluble 
α-klotho in FGF23 signaling have not been identified. Soluble α-klotho displays 
an enzymatic activity that may be important in regulating ion channels such as 
the sodium-phosphate co-transporter (NaPi-IIa), renal outer medullary 
potassium (ROMK) channel and transient receptor potential vanilloid (TRPV5) 
ion channel(176). 
Increased FGF23 serum levels following lithium treatment in acute depressive 
patients were paralleled with a significant decrease in 1,25(OH)2D3 serum 
levels. This effect could be explained by an increase FGF23 serum level. 
FGF23 acts as a counter-regulatory hormone for 1,25(OH)2D3. In other words, 
FGF23 could suppress 1α-hydroxylase activity in the proximal renal tubule, 
leading to reduced circulating levels of 1,25(OH)2D3 (129). 
1,25(OH)2D3 stimulates the renal and intestinal phosphate transport. FGF23 has 
been regarded as a main phosphaturic factor. It regulates the phosphate 
homeostasis through its direct inhibitory effects on the expression of NaPi-IIa 
and NaPi-IIc in the renal tubule as well as through the inhibition of the renal 
synthesis of 1,25(OH)2D3. Therefore, the FGF23 reduces the intestinal 
phosphate absorption indirectly through its effects on 1,25(OH)2D3 (116).  
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Based on my findings, an increase in FGF23 serum level following lithium 
treatment in acute depressive patients could account for the observed decrease 
of serum phosphate concentration. Lithium treatment tends to decrease the 
serum calcium level in acute depressive patients, an effect, however not 
reaching the statistical significance. Urinary calcium and phosphate excretion in 
the clinical samples was not investigated and therefore it is difficult to interpret 
the relevance of phosphate homeostasis in response to lithium treatment in 
human (patho)physiology. 
As mentioned above, FGF23 ablation results in elevated serum phosphate, 
calcium, and 1,25-dihydroxyvitamin D3 levels, vascular calcifications, and early 
death. Vascular calcification was considered to be a passive, degenerative, and 
end-stage process of vascular disease. However, several observations have 
challenged this hypothesis and linked high serum phosphate level (i.e., higher 
than the normal adult range of 1.0 to 1.5 mmol/L) with the development of 
vascular calcification (110-112).  
This study might partly explain these findings as lithium might decrease the 
phosphate concentration, vascular calcification and thereby increase the life 
span. Furthermore, these findings are in line with evidence which implicated 
that even low levels of lithium in drinking water may protect against suicide and 
promote longevity in humans (177-180). Moreover, recent studies demonstrate 
that long-term low-dose exposure to lithium may exert anti-aging capabilities 
and decrease mortality in distinct species (12).  
The anti-depressant mechanism that may underline the observed effect of 
lithium on FGF23 in those patients might be the proper formation of synaptic 
connection, maturation and survival of catecholamine neurons and 
neurogenesis.  
 
 
 
57 
 
5.3 Limitations of the study 
  
During this study I acquired a number of laboratory skills ranging from cell 
culture to RTQ-PCR, Western blot analysis and ELISA. Nevertheless, I 
encountered a number of limitations, the majority of which were dealt with 
through trial and error. For example, the validity of measuring the serum klotho 
level in the clinical samples using ELISA method. Since soluble α-klotho is 
being produced by extrarenal tissue. Moreover, the cross reactivity with other 
analytes cannot be excluded (181, 182).  
One drawback of this study was the small sample size for each patient group; 
however collection and analysis of more samples would strengthen the validity 
of some of our current data. Furthermore, no placebo-treated group was 
observed, and the effects on FGF23 and 1,25(OH)2D3 were rather small in 
magnitude. However, small effects might cause changes when medications are 
used chronically.  
Furthermore, the main limitation of lithium treatment is its narrow therapeutic 
index and requirement of close medical supervision. The debate about the risk 
of kidney damage is another concern which remained controversial. However, a 
recent 2-year randomized, placebo-controlled trial study demonstrated that 
chronic use of lithium at low doses did not affect renal function and was 
clinically safe (177). 
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5.4 Conclusion 
 
In conclusion, I present conclusive evidence implicating the effect of lithium on 
FGF23 hormonal axis. As mentioned above, a short-duration lithium treatment 
was parallel with a significant increase in FGF23 serum level, decrease of 
serum 1,25(OH)2D3 and phosphate concentration. In the murine experiments, 
these effects were paralleled by a statistically significant decrease of renal 
klotho expression, an increase in the renal GSK-3 phosphorylation and the 
renal phosphate excretion. The lithium treatment tends to decrease the serum 
calcium level in both experiments, an effect, however not reaching the statistical 
significance. These effects could be medically useful against vascular 
calcification and the appearance of age-related disorders. 
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6 Summary 
 
Lithium is one of the oldest drugs used in Neuropsychopharmacology (183), 
and still remains a first-line therapy in bipolar mood disorders. Lithium is at least 
partially effective by inhibiting the glycogen synthase kinase 3 (GSK-3), which in 
turn regulates aquaporin 2 water channels via adenylate cyclase or 
prostaglandin-E2 (32, 184). Further, lithium treatment has been demonstrated 
as one of the most common causes of drug-induced nephrogenic diabetes 
insipidus (NDI), leading to renal water loss. Dehydration has in turn been shown 
to downregulate klotho, which is required as a co-receptor for fibroblast growth 
factor 23 (FGF23) (144, 145).  
FGF23 is a potent inhibitor of aging. FGF23 deficiency is followed by increased 
levels of serum phosphate, calcium, and 1,25(OH)2D3 concentrations with 
subsequent vascular calcification, decrease of bone density and reduction of life 
span (118, 158, 185, 186). More recently, there is growing evidence suggesting 
that low-dose lithium treatment may exert anti-aging capabilities and promote 
longevity in humans (12, 178, 180).  
The present study explored whether lithium treatment influences the renal 
expression and serum level of klotho, FGF23 serum concentration, 1,25(OH)2D3 
formation, urinary excretion and serum concentration of phosphate and calcium.  
To this end, 10 week-old female C57BL/6 mice were analysed after a 14-day 
period of treatment with NaCl or LiCl (200 mg/kg/day subcutaneously). 
Additionally, a total of 95 acute depressive patients were recruited who received 
lithium carbonate treatment as an augmenting agent for 4 weeks. All patients 
reached a lithium serum level of more than 0.4 mmol/l. Blood samples from 
those patients were drawn before and 4 weeks following lithium augmentation.  
In the murine experiments, the serum ADH, FGF23, and 1,25(OH)2D3 
concentrations were determined by ELISA. Renal klotho protein abundance and 
GSK-3 phosphorylation were analysed by Western blot and the urinary and 
serum phosphate and calcium concentration by photometry.  
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In the human experiments, the FGF23, soluble α-klotho, 1,25(OH)2D3, 
phosphate and calcium concentrations were measured in serum samples of 
acutely depressive patients before and 4 weeks after lithium augmentation. 
Both lines of evidence from murine and human experiments revealed that 
lithium treatment resulted in a pronounced increase in the FGF23 serum level, 
and a significant decrease of serum 1,25(OH)2D3 and phosphate concentration. 
In the murine experiments, these effects were paralleled by a statistically 
significant decrease in the renal klotho expression, and increase in renal 
phosphate excretion. The lithium treatment tended to decrease the serum 
calcium level in mice. 
In conclusion, this study presents conclusive evidence that lithium upregulates 
FGF23 formation, an effect paralleled by a substantial decrease of serum 
1,25(OH)2D3, and phosphate concentrations. These effects could possibly 
counteract vascular calcification and the onset of age-related disorders. Our 
observation might partly explain the mechanism through which lithium improves 
survival and promotes longevity in humans.  
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Zusammenfassung 
 
Lithium ist eines der ältesten Medikamente die in der 
Neuropsychopharmakologie eingesetzt werden (183) und stellt noch immer eine 
Therapie erster Wahl als Behandlungsoption bei bipolaren affektiven Störungen 
dar. Lithium entfaltet seine Wirkung zumindest teilweise durch die Hemmung 
der Glykogensynthase-Kinase 3 (GSK-3), welche den Aquaporinkanal 2 via 
Adenylylcyclase oder Prostaglandin E2 reguliert (32, 184). Die Lithium-
Behandlung ist zudem eine der häufigsten Ursachen für den 
arzneimittelinduzierten Nephrogenen Diabetes Insipidus (NDI), welcher zu 
renalem Wasserverlust führt. Bereits gezeigt wurde, dass Dehydratation mit 
einer Hemmung des Klotho-Proteins einhergeht, das als obligater Kofaktor für 
den Fibroblasten-Wachstumsfaktor (FGF23) dient (144, 145).  
FGF23 unterdrückt effektiv den Alterungsprozess. Ein Mangel an FGF23 führt 
zu einer Erhöhung der Serumphosphat-, Kalzium- und 1,25(OH)2D3-
Konzentrationen, gefolgt von vaskulärer Kalzifikation, Abnahme der 
Knochendichte und Erniedrigung der Lebenserwartung (118, 158, 185, 186). 
Seit kurzem gibt es vermehrt Hinweise darauf, dass die Behandlung mit niedrig 
dosiertem Lithium einen Anti-Aging Effekt ausübt und eine positive Auswirkung 
auf die Lebenserwartung beim Menschen zeigt (12, 178, 180).  
Diese Studie beschäftigt sich mit der Frage, ob eine Lithium-Behandlung die 
renale Expression und den Serumspiegel von Klotho, die FGF23- 
Serumkonzentration, die 1,25(OH)2D3-Bildung, sowie die renale Ausscheidung 
und die Serumkonzentration von Phosphat- und Kalzium beeinflusst. Zu diesem 
Zweck wurden 10 Wochen alte C57BL/6 Mäuse (Weibchen) nach einer 14-
tägigen Behandlungsperiode mit NaCl oder Lithium (LiCl) (200 mg/kg/d 
subkutan) untersucht. Darüber hinaus wurden 95 akut depressive Patienten 
rekrutiert, die eine Lithiumkarbonat-Behandlung als zusätzliche Therapie über 
einen Zeitraum von vier Wochen erhielten. Alle Patienten erreichten ein 
Serumlevel von mehr als 0.4mmol/l. Von diesen Patienten wurden Blutproben 
vor und nach der vierwöchigen Behandlung entnommen.  
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Im Mausexperiment wurden zudem die Serumkonzentrationen von ADH, 
FGF23 sowie 1,25(OH)2D3 mittels ELISA bestimmt. Mit Hilfe der Western Blot-
Technik wurde die renale Klotho-Proteinmenge und die GSK-3 
Phosphorylierung analysiert. Die Urin- und Serumkonzentrationen von 
Phosphat und Kalzium wurden photometrisch bestimmt. 
Im Humanexperiment wurden die Serumkonzentrationen von FGF23, dem 
zirkulierenden α-Klotho, von 1,25(OH)2D3 sowie die Phosphat- und 
Kalziumkonzentrationen der Patienten vor der Lithiumbehandlung und vier 
Wochen nach der Lithiumbehandlung gemessen. 
Sowohl die Resultate der Maus- als auch der Humanexperimente zeigen, dass 
eine Behandlung mit Lithium mit einer erheblichen Erhöhung des FGF23-
Serumlevels und einer signifikanten Erniedrigung des 1,25(OH)2D3 sowie der 
Phosphatkonzentration einhergeht. Im Mausversuch zeigte sich zusätzlich zu 
diesen Effekten noch eine statistisch signifikante Erniedrigung der renalen 
Klotho-Expression und eine Erhöhung der renalen Phosphatausscheidung. Die 
Lithiumbehandlung bewirkte auch eine tendenziell niedrigere 
Serumkalziumkonzentration bei den Mäusen.  
Zusammenfassend präsentiert diese Studie schlüssige Beweise, dass Lithium 
die FGF23-Bildung hochreguliert, ein Effekt, welcher mit einer Erniedrigung der 
Serum 1,25(OH)2D3- und Phosphatkonzentrationen einhergeht. Diese Effekte 
könnten möglicherweise der Bildung von vaskulären Kalzifikationen und dem 
Auftreten von altersbedingten Krankheiten entgegenwirken. Unsere 
Beobachtungen könnten teilweise den Mechanismus erklären, durch welchen 
Lithium die Überlebensrate begünstigt und eine höhere Lebensdauer beim 
Menschen fördert. 
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